NGNE · Neurogene
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $28.50
Note written ·
How this view changed
- · Rating cut from Medium to Low. The note's kill line was crossed, 12 November 2026: The shares closed at $23.90 on 12 November 2026, below the published $24.00 kill line, after the 9 November 2026 third-quarter report raised the Embolden success bar to 9 of 25 responders.
Price against the kill line
16.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $28.50, set on 13 November 2026. The shares are down 34.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $28.50, over both the 50-day and 200-day moving averages, which would show the shares leading again. An Embolden topline with at least 9 of 25 responders would also show the case working.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 31 December 2025, filed 24 March 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Free cash flow, four quarters ($M)
- −97.5
- Free-cash-flow yield (%)
- −19.7
All filed numbers
What Neurogene reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) |
|---|---|---|
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | −100.0 |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −119 | −29.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +30.8 |
| Operating cash flow ($M) | −96.5 |
| Capital spending ($M) | 1.1 |
| Free cash flow ($M) | −97.5 |
| Cash and short-term investments ($M) | 360 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 355 |
| Market value ($M) | 495 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.4 |
| Free-cash-flow yield (%) | −19.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 24.6% of shares outstanding sold short, 14.4 days of average trading to cover, +2.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $1.1M |
The thesis
Neurogene's Rett syndrome gene therapy, NGN-401, is funded into the first quarter of 2029, but the shares are more likely to lag the S&P 500 over the next three months. They closed at $23.90 on 12 November 2026, below the 50-day average of $28.49 and the 200-day average of $28.14. The Embolden trial topline, guided to the second half of 2027, settles the case.
The $24.00 kill line was crossed on 12 November 2026, when the shares closed at $23.90. The close followed $25.10 on 11 November 2026 and $26.00 on 9 November 2026, the day of the third-quarter report. The crossing showed that the post-report selling had not found a floor, and it moves the call from a modest lead to a lag.
The report itself held the runway and the timelines. Neurogene reported $359.7 million of cash and short-term investments at 30 September 2026, a runway into the first quarter of 2029, and a topline still due in the second half of 2027. It also raised the Embolden success bar. Because the trial was overenrolled, all 25 dosed participants enter the primary analysis, and the threshold is now 9 responders, or 36%.
Bullish and bearish views on Neurogene Inc.
The bull case on Neurogene Inc. (NGNE), in brief: cash covers the readout. The bear case: the shares sit below the offering price and the averages.
Bull case
- Cash covers the readout. Neurogene held $359.7 million at 30 September 2026, and the company says it funds planned operations into the first quarter of 2029 (third-quarter release, 9 November 2026). The third-quarter net loss was $29.0 million, down from $34.5 million in the second quarter.
- Trial design is aligned with the FDA. The update to the statistical analysis plan was aligned with the agency through the START Pilot Program (company release, 9 November 2026). NGN-401 also holds Breakthrough Therapy designation.
- Early efficacy was uniform. All 10 Phase 1/2 participants improved on the Clinical Global Impression–Improvement scale. Each gained at least one developmental milestone, 47 in total, through up to 30 months of follow-up (data cutoff 16 June 2026, company release of 11 August 2026).
- Safety has held at the chosen dose. The company described the 1E15 vector-genome dose as generally well tolerated in 35 participants as of 8 November 2026.
- Manufacturing is on schedule. Qualification runs supporting the Biologics License Application are on track for completion by year-end 2026 (company release, 9 November 2026).
- Analysts remain constructive. HC Wainwright maintained a Buy rating and lowered its target to $60 on 10 November 2026. J.P. Morgan initiated at Overweight with a $60 target on 8 October 2026. Jennison Associates reported an 11.1% stake as of 30 September 2026.
Bear case
- The shares sit below the offering price and the averages. The July 2026 offering priced stock at $30.00 (Benzinga, 1 July 2026). The 12 November 2026 close of $23.90 is 33.9% lower than three months earlier and 45.3% below the 52-week intraday high of $43.66 set on 9 July 2026.
- The success bar is higher. The threshold moved to 9 of 25 responders (36%), from the 8 of 24 (33%) the company had used (company release, 9 November 2026). The endpoint is open-label and rated by clinicians and caregivers.
- Spending is rising. Third-quarter research and development expense was $23.5 million against $17.2 million a year earlier, and general and administrative expense was $8.9 million against $6.6 million (company release, 9 November 2026).
- A competitor reads out first. Taysha Gene Therapies finished dosing 17 participants in its pivotal REVEAL trial of TSHA-102 and guides to a six-month interim plus FDA filing-path feedback in the first half of 2027 (Taysha release, 11 August 2026). Those data will frame expectations for Embolden before Neurogene's topline.
- One asset carries the equity. NGN-401 is effectively the whole company. A high-dose patient died of hemophagocytic lymphohistiocytosis in November 2024, which shows how fast a safety event can reprice the shares.
Price setup
The last close was $23.90 on 12 November 2026. That is below the 15 October 2026 close of $23.95 and below the 50-day average of $28.49 and 200-day average of $28.14. Both averages are now above the shares. The closes since the report ran $26.00 on 9 November 2026, $25.28 on 10 November 2026, $25.10 on 11 November 2026 and $23.90 on 12 November 2026.
The 52-week closing low is $16.37 on 5 February 2026, and the 52-week intraday high is $43.66 on 9 July 2026. The $30.00 July offering price sits above the current market and above both averages. The 28 October 2026 close of $30.42 is the recent test of that level.
Volume is thin. MarketBeat put average volume at 215,471 shares on 28 October 2026, so a single headline can move the price. The Embolden topline is more than a year away, so over three months the shares depend on the Taysha read-through, the manufacturing milestone, and the supply of offering stock.
Catalysts ahead
- 31 December 2026: Guided completion of NGN-401 manufacturing qualification runs. A gating input for a Biologics License Application; slippage would push the commercial timeline out regardless of clinical results.
- ~30 June 2027 (est.): Taysha REVEAL six-month interim and FDA filing-path feedback (guided for the first half of 2027). Likely the first pivotal Rett gene therapy readout; a weak result would pressure the whole group, a strong one would raise the bar for Embolden.
- ~31 December 2027 (est.): Embolden topline (guided for the second half of 2027). The deciding event: at least 9 of 25 responders is the stated success bar.
What would change the view
A daily close above $28.50, over both the 50-day and 200-day moving averages, which would show the shares leading again. An Embolden topline with at least 9 of 25 responders would also show the case working.
The line before it, a daily close below $24.00 set on 9 November 2026, was crossed on 12 November 2026: the shares closed at $23.90.
What it trades with
Neurogene trades most closely with Taysha Gene Therapies (TSHA), the other company with a Rett gene therapy in a pivotal trial. Taysha reported on 12 November 2026, the day Neurogene closed at $23.90, and its first-half 2027 interim is the direct read-through. Beyond that pair, the shares follow small-cap biotech sentiment and the rare disease gene therapy group, where FDA decisions and safety events at peers can reprice the group. Until Embolden reads out, company results bring cash and timeline updates, with no revenue line to move the shares.
The evidence, claim by claim (8)
- Cash, cash equivalents and short-term investments of $359.7 million at 30 September 2026 ($78.9 million cash, $280.8 million short-term investments); runway into the first quarter of 2029. Neurogene third-quarter 2026 results release · as of
- Third-quarter net loss of $29.0 million, or $1.05 per share, against $21.0 million a year earlier; research and development expense $23.5 million against $17.2 million; general and administrative expense $8.9 million against $6.6 million. Neurogene third-quarter 2026 results release · as of
- Embolden is overenrolled; all 25 dosed participants enter the primary efficacy analysis, and the success threshold is 9 of 25 responders (36%). The statistical analysis plan update was aligned with the FDA through the START Pilot Program. Neurogene third-quarter 2026 results release · as of
- NGN-401 at the 1E15 vector-genome dose remained generally well tolerated in 35 participants across the Phase 1/2 trial and Embolden, data cutoff 8 November 2026; manufacturing qualification runs are on track for completion by year-end 2026. Neurogene third-quarter 2026 results release · as of
- Neurogene reported a third-quarter loss of $1.05 per share against a $1.36 loss estimate. News reports on the 9 November 2026 results · as of
- HC Wainwright maintained a Buy rating on Neurogene and lowered its price target to $60. HC Wainwright note reported 10 November 2026 · as of
- Taysha completed dosing of 17 participants in the REVEAL pivotal trial of TSHA-102; six-month interim data and FDA feedback on the filing path are guided to the first half of 2027; cash of $455.4 million at 30 June 2026 funds operations into the second half of 2028. Taysha second-quarter 2026 results release (Form 8-K) · as of
- Jennison Associates reported a 11.1% stake as of 30 September 2026 in a Schedule 13G. SEC Schedule 13G, reported 6 October 2026 · as of
Sources
- Topline data from Embolden™ registrational trial anticipated in 2H 2027 · biospace.com ·
- Neurogene Inc. - Form 8-K - FY2026 · sec.gov ·
- Taysha Gene Therapies, Inc. - Form 8-K - FY2026 · sec.gov ·
- Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 · finviz.com
Related · shared themes
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
PVLA
Palvella Therapeutics
Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no…
CAPR
Capricor Therapeutics
Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against…
CRSP
CRISPR Therapeutics
CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November…
See also · stocks to watch